Scholar Rock Holding Corporation (SRRK) Stock: Price, Forecast & Analyst Target
Scholar Rock Holding Corporation (SRRK) — MoonshotScore 44/100 (Weak band), calculated Oct 6, 2026. Price $43.40 (-7.28%), as of the Oct 5, 2026 trading session; market cap $5.20B. Expected results Nov 13, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 10.57× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 13, 2026
Scholar Rock Holding Corporation · SRRK · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Scholar Rock develops treatments that target protein growth factor signaling, anchored by a late-stage candidate for spinal muscular atrophy. Because the company currently generates no commercial revenue, the investment case rests entirely on whether its clinical trial data can secure regulatory approval and transition the pipeline into a marketed product.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Scholar Rock Holding (SRRK)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a strained balance sheet and stalling growth. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.
- quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 0 of 8
- Altman Z 6.91 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 45 | Weak | |
| 45 | Fair | |
| 45 | Fair | |
| 45 | Weak | |
| 45 | Weak | |
| 45 | Weak |
The score moved from 45 in the stored Oct 5, 2026 snapshot to 44 in the current publication computed Oct 6, 2026 (-1); the largest pillar moves were Momentum -11. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $43.40 | |
| Change on the day | -7.28% | |
| 52-week range | $27.07 – $61.76 | |
| Market capitalisation | $5.20B | |
| Price / earnings (trailing) | -21.42 | |
| Shares traded on the day | 3.35M | |
| Beta (volatility vs the S&P 500) | 0.68 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Scholar Rock Holding (SRRK): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the SRRK film — every key number, told as a short cinematic story
~2 min · open the film
What is Scholar Rock Holding (SRRK), and what does it report?
Short answer · as of
Scholar Rock operates as a clinical-stage biopharmaceutical developer focused on serious diseases like spinal muscular atrophy and treatment-resistant cancers.
Research dated 2026-09-13.
Scholar Rock operates as a clinical-stage biopharmaceutical developer focused on serious diseases like spinal muscular atrophy and treatment-resistant cancers. Although the standard industry classification groups it with broad healthcare providers, the business functions strictly as a research engine that consumes cash to advance experimental therapies through trials.
Its income statement measures the heavy cost of scientific development against a complete lack of commercial sales, with research and development expenses constituting the bulk of its operational drain.
What do the latest results show for Scholar Rock Holding (SRRK)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0.
Research dated 2026-09-13.
The latest financial results show widening net losses as the company funds late-stage clinical evaluations for its lead spinal muscular atrophy candidate. Without product revenue to offset costs, operating deficits grow directly in proportion to the rising expenses of clinical trials and administrative overhead.
This reporting period reflects a pure consumption phase where development milestones dictate the velocity of cash burn.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $58.23M Jun 30, 2026
- Latest quarter · SG&A
- $50.67M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$108.90M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | $58.23M | $50.67M | −$108.90M |
| Mar 31, 2026 | Not available | $51.81M | $50.20M | −$102.02M |
| Dec 31, 2025 | Not available | $46.88M | $45.02M | −$91.90M |
| Sep 30, 2025 | Not available | $50.49M | $53.06M | −$103.55M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue estimate
- $70,000 Aug 6, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | Not available | $70,000 | −$0.8400 | −$0.8405 |
| May 7, 2026 | Not available | $5.00M | −$0.8300 | −$0.8200 |
| Mar 3, 2026 | Not available | $1.83M | −$0.8800 | −$0.8825 |
| Nov 14, 2025 | Not available | $50,000 | −$0.9000 | −$0.8352 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$110M | -$0.84 (diluted) |
| Q1 FY2026 | $0 | -$106M | -$0.83 (diluted) |
| Q4 FY2025 | $0 | -$91M | -$0.79 (diluted) |
| Q3 FY2025 | $0 | -$102M | -$0.90 (diluted) |
What are the financial strengths and risks for Scholar Rock Holding (SRRK)?
Short answer
Cash and short-term investments were $492.09M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$69.64M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The balance sheet is structured around cash reserves, which must fund all clinical programs until a drug reaches the market or a new financing event occurs. Current liquidity holds a comfortable margin over the near-term cash burn rate, providing a temporary runway for continued research.
The primary risk lies in trial failure or regulatory delay, which would force the company to raise fresh capital under distressed conditions before securing a commercial revenue stream.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$69.64M Jun 30, 2026
- Previous quarter · operating cash flow
- −$82.10M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$69.64M | $0.00 |
| Mar 31, 2026 | −$82.10M | −$70,000 |
| Dec 31, 2025 | −$75.50M | −$30,000 |
| Sep 30, 2025 | −$68.92M | −$80,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Scholar Rock Holding (SRRK)?
Short answer · as of
The next earnings report is expected on Nov 13, 2026.
Research dated 2026-09-13.
Market watchers are closely tracking upcoming financial disclosures for updates on the clinical timeline of the lead spinal muscular atrophy asset and the early-stage solid tumor program. Cash runway projections remain the most critical metric in upcoming filings, as any acceleration in research spending shortens the window before the company must secure additional funding.
Furthermore, observers monitor the ongoing partnership with Gilead Sciences for any milestone progress in their joint fibrotic disease pipeline.
How does Scholar Rock Holding compare with its peers?
Short answer
Scholar Rock Holding's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Unlike commercial-stage biotechnology firms that balance research spending with drug sales, Scholar Rock is defined entirely by its unapproved pipeline. Its specific focus on inhibiting the activation of latent myostatin distinguishes its scientific approach from peers utilizing standard gene therapies or broad immunosuppressants.
The heavy concentration of institutional ownership suggests the market treats the stock as a binary bet on its unique protein growth factor signaling platform rather than a traditional fundamental investment.
| Company | Price | Market value | Score |
|---|---|---|---|
| $306.77 Oct 5, 2026 | $6.15B | 96 5-pillar Oct 6, 2026 | |
| $47.67 Oct 5, 2026 | $3.71B | 96 5-pillar Oct 6, 2026 | |
| $20.11 Oct 5, 2026 | $3.44B | 76 5-pillar Oct 6, 2026 | |
| $159.18 Oct 5, 2026 | $6.40B | 69 5-pillar Oct 6, 2026 | |
| $84.38 Oct 5, 2026 | $5.09B | 68 5-pillar Oct 6, 2026 | |
| $40.30 Oct 5, 2026 | $4.34B | 66 5-pillar Oct 6, 2026 | |
| $53.91 Oct 5, 2026 | $8.18B | 65 5-pillar Oct 6, 2026 | |
| $118.87 Oct 5, 2026 | $4.97B | 64 5-pillar Oct 6, 2026 | |
| $42.76 Oct 5, 2026 | $7.17B | 64 5-pillar Oct 6, 2026 | |
| $14.72 Oct 5, 2026 | $5.06B | 62 5-pillar Oct 6, 2026 | |
| $37.57 Oct 5, 2026 | $3.63B | 56 5-pillar Oct 6, 2026 | |
| $76.31 Oct 5, 2026 | $5.82B | 48 5-pillar Oct 6, 2026 | |
| Scholar Rock Holding (SRRK) — this page | $43.40 | $5.20B | 44 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $58.00 – $84.00
- Consensus target
- $70.45
- Median target
- $70.00
Consensus record · Captured .
Measured against a quoted price of $43.40 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 24, 2026
- Transactions
- 41
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 17
- Other transactions
- 24
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 317 Period end Jun 30, 2026
- Previous quarter · holders
- 291 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 17,995,241 |
| Siren, L.L.C. | 9,575,013 |
| Blackrock, INC. | 9,494,084 |
| Samsara Biocapital, LLC | 6,897,652 |
| Price T Rowe Associates INC /Md/ | 6,794,837 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Scholar Rock Holding (SRRK)?
SRRK Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does the Gilead Sciences partnership affect the pipeline?
The strategic collaboration focuses on developing targeted inhibitors for fibrotic diseases. This partnership allows the company to expand its therapeutic reach beyond core muscular and oncology programs without bearing the entire research burden alone, a crucial benefit for a pre-revenue biopharmaceutical firm.
Why are net losses growing despite successful clinical trial conclusions?
Advancing a therapeutic candidate through late-stage development and preparing for potential commercialization requires aggressive spending on research and administration. Because the company generates no product sales, these escalating trial costs flow directly to the bottom line as widening losses.
What provides the capital runway for the apitegromab regulatory review process?
The company maintains a substantial reserve of cash and short-term investments that comfortably exceeds its annualized operating cash drain. This liquidity buffer is designed to fund operations through the immediate clinical milestones without requiring imminent equity dilution.
Are corporate insiders accumulating shares as the lead therapy nears potential approval?
Recent filings show a pattern of net selling among corporate officers. Distinct insiders have disposed of shares over the trailing period, opting for liquidity rather than accumulating more equity as the clinical pipeline advances.
What is the SRRK stock price today?
The last price recorded on this page for Scholar Rock Holding Corporation (SRRK) is $43.40, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SRRK price target?
The analyst consensus price target for Scholar Rock Holding Corporation (SRRK) is $70.45 (range $58.00 to $84.00, median $70.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (69 figures)
The 69 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 301 Binney Street, 3RD Floor, Cambridge, MA, 02142 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "301 Binney Street, Cambridge, MA, 02142, US". |
FMP — 61 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 13, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $43.40 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-06T00:35:08.864Z. | |
px.change | Change on the day | -7.28% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.20B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:00.000Z. Captured from FMP at 2026-10-06T00:35:03.447Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$3.41 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -21.42 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.35M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.68 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | David L. Hallal | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 289 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $18.82M, net result −$131.80M; FY2022 revenue $33.19M, net result −$134.50M; FY2023 revenue $0.00, net result −$165.79M; FY2024 revenue $0.00, net result −$246.29M; FY2025 revenue $0.00, net result −$377.94M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $58.23M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $50.67M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$108.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $51.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $50.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$102.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $46.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $45.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$91.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $50.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $53.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$103.55M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-06.revenue_estimated | Revenue · estimate — report date 2026-08-06 | $70,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | −$0.8400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | −$0.8405 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $5.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | −$0.8300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | −$0.8200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.revenue_estimated | Revenue · estimate — report date 2026-03-03 | $1.83M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.eps_actual | EPS · reported — report date 2026-03-03 | −$0.8800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.eps_estimated | EPS · estimate — report date 2026-03-03 | −$0.8825 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.revenue_estimated | Revenue · estimate — report date 2025-11-14 | $50,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.eps_actual | EPS · reported — report date 2025-11-14 | −$0.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-14.eps_estimated | EPS · estimate — report date 2025-11-14 | −$0.8352 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $492.09M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$69.64M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $203.83M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 24.09× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$69.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$82.10M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$70,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$75.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$30,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$68.92M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$80,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $58.00 – $84.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $70.45 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $70.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 41 transactions · 0 purchases, 17 sales, 24 other transactions · 11 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 24, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 317 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 291 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 17,995,241 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Siren, L.L.C. — shares in provider snapshot | 9,575,013 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Blackrock, INC. — shares in provider snapshot | 9,494,084 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Samsara Biocapital, LLC — shares in provider snapshot | 6,897,652 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 6,794,837 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 0 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-20 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 6.91 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $27.07 – $61.76 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 10.57× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $492.09M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.8400) with the recorded estimate (−$0.8405) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 44 of 100 · Weak · pillars 34 / 30 / 45 / 9 / 51 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 45 (stored snapshot Oct 5, 2026) → 44 (current publication computed Oct 6, 2026) (-1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.revenue_estimated,earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-03-03.revenue_estimated,earn.history.depth.2026-03-03.eps_actual,earn.history.depth.2026-03-03.eps_estimated,earn.history.depth.2025-11-14.revenue_estimated,earn.history.depth.2025-11-14.eps_actual,earn.history.depth.2025-11-14.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2836 — Biological Products, (No Diagnostic Substances). | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Cash, investments and debt | Total debt: $203.83M; Liquidity basis: cash and short-term investments; Total liabilities: $269.76M; Cash and short-term investments: $492.09M; Cash and investments: $492.10M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash runway cross-check (ours) | Years: 1.8; Method: cash and short-term investments of $492.1M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($277.2M per year); Reaches: 2028-04; Cash basis: cash and short-term investments; Cash: $492.10M; Annualized cash use: $277.20M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Next earnings report | Date: 2026-11-13; EPS estimate: -$0.87 per share; Revenue estimate: $75,000 The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Recent SEC filings |
| 2026-08-06 | OFFICIAL | SEC EDGAR filer submissions |
| Institutional ownership (13F) | Holders: 317; Quarter: 2026-06-30; Holders previous quarter: 291 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Insider transactions, last 180 days | Net shares: -2,597; Window days: 180; Price low: $4.75; Clustered days: 2026-04-16; 2026-06-04; 2026-07-01; Price high: $54.96; Buy transactions: 0; Distinct insiders: 11; Sell transactions: 17; Other transactions: 22; Total transactions: 39; Other transaction types: A-Award: 14, M-Exempt: 8; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-07-01 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Named officers | CEO: David L. Hallal; Officers: Rushmie Nofsinger — Title: Vice President of Corporate Affairs & Investor Relations; Robert Keith Woods — Title: Chief Operating Officer, Pay: $1.11M, Born: 1968; Vikas Sinha — Title: CFO & Treasurer, Pay: $1.06M, Born: 1963; Junlin — Title: General Counsel & Corporate Secretary, Pay: $563,729, Born: 1979; Caryn Parlavecchio — Title: Chief Human Resources Officer, Born: 1972; Erin Moore — Title: Interim Principal Financial & Accounting Officer, Born: 1975; Lisa Wyman — Title: Chief Technical & Quality Officer, Born: 1978; David L. Hallal — Title: Chief Executive Officer & Chairman of the Board, Pay: $3.16M, Born: 1966 Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
| Most recent Schedule 13D | Form: SC 13D/A; Filed: 2024-10-07 A Schedule 13D is filed by a holder of more than 5% who is not a passive investor. | 2024-10-07 | OFFICIAL | SEC EDGAR — SC 13D/A |
Data provided for informational purposes only.
ETFs that hold SRRK
Funds in our ETF coverage that list SRRK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 4.06% |